Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare leader formed through the merger of Upjohn and Mylan, delivering essential medicines across 165+ countries. This page provides centralized access to official corporate announcements and market-moving developments.
Investors and analysts will find timely updates including earnings reports, regulatory milestones, and strategic partnerships. Track the company’s progress in generic pharmaceuticals, biosimilars, and therapeutic innovations through verified press releases.
Our curated news feed serves as a reliable resource for understanding Viatris’ operational decisions, product pipeline advancements, and global healthcare initiatives. Bookmark this page to stay informed about one of the pharmaceutical industry’s most diversified companies.
Viatris Inc. (NASDAQ: VTRS) announced a significant legal victory as the U.S. Court of Appeals for the Federal Circuit upheld the invalidity of Biogen's U.S. Patent No. 8,399,514, which covers its multiple sclerosis drug, Tecfidera®. The court denied Biogen's request to reconsider its earlier ruling, reinforcing that the patent remains invalid. This decision is crucial for Viatris, particularly after its subsidiary, Mylan Pharmaceuticals, launched the first generic equivalent of Tecfidera in August 2020, potentially enhancing market competition and access for patients.
Viatris Inc. (NASDAQ: VTRS) has received FDA approval for Breyna™, the first generic version of AstraZeneca's Symbicort® inhalation aerosol, in partnership with Kindeva Drug Delivery. Available in two dosage strengths, Breyna is indicated for asthma and COPD patients, providing a new treatment option to millions. This approval showcases Viatris' expertise in developing complex generic medicines and supports their mission to enhance patient access. The launch is expected in 2022, subject to ongoing court proceedings that may influence market entry.
Viatris Inc. (NASDAQ: VTRS) announced its participation in two upcoming investor conferences. CEO Michael Goettler and CFO Sanjeev Narula will take part in a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference on March 8 at 3:25 p.m. EST. Additionally, Rajiv Malik, President, and CFO Narula will participate in the Barclays Global Healthcare Conference on March 16 at 10:45 a.m. EST. Live webcasts will be available at investor.viatris.com.
Viatris announced a significant transaction involving Biocon Biologics, with a pre-tax consideration of up to $3.335 billion. This includes $2 billion in upfront cash, $1 billion in convertible preferred equity, and up to $335 million in additional payments. Viatris' President, Rajiv Malik, will join Biocon Biologics' Board. The transaction is expected to close in the second half of 2022, enhancing capital availability for reinvestment and simplifying operational complexity. Viatris also provided 2022 financial guidance, projecting an adjusted EBITDA of approximately $200 million for its biosimilars portfolio.
Viatris Inc. (NASDAQ: VTRS) will host an investor event on February 28, 2022, at 8:30 a.m. ET, where the CEO, President, and CFO will present the company's fourth quarter and full year 2021 financial results. The event will provide insights into Viatris' two-phased strategic roadmap. Interested investors can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris focuses on delivering high-quality medicines globally, with over 1,400 approved molecules across various therapeutic areas.
Viatris Inc. (NASDAQ: VTRS) announced FDA approval for Cyclosporine Ophthalmic Emulsion 0.05%, the first generic version of Allergan's Restasis®, allowing immediate market launch. With no remaining regulatory barriers, Viatris aims to enhance access to affordable treatments for chronic dry eye disease. This approval represents a significant milestone for Viatris, highlighting its commitment to innovation and patient access.
Viatris Inc. (NASDAQ: VTRS) announced a 9% increase in its quarterly dividend, now set at 12 cents ($0.12) per share, payable on March 16, 2022. This marks the fourth consecutive quarterly dividend declaration, positioning the annual dividend rate for 2022 at 48 cents ($0.48) per share. CEO Michael Goettler expressed satisfaction with the company's operational momentum and commitment to returning capital to shareholders. The record date for this dividend is February 24, 2022.
Viatris Inc. (NASDAQ: VTRS) announced that the U.S. Patent and Trademark Appeal Board affirmed its previous rulings declaring several of Sanofi's Lantus® SoloSTAR® device patents unpatentable. This decision is a significant win for Viatris, facilitating wider access to its interchangeable Semglee® products, which are now the only interchangeable biosimilars for Lantus®. These products aim to provide affordable insulin options for diabetes patients, allowing substitution at pharmacies. Viatris' commitment to enhancing patient access is evident through its Global Healthcare Gateway® initiative.
Viatris Inc. (NASDAQ: VTRS) has announced a rescheduling of its investor event from January 7, 2022, to a date no later than February 28, 2022, coinciding with the release of its fourth quarter 2021 results. The company reaffirmed its 2021 financial guidance originally provided on November 8, 2021. During the event, Viatris will present details on its two-phased strategic roadmap, covering financial guidance and metrics for Phase I (2022-2023) and growth catalysts for Phase II (2024 and beyond), including capital allocation priorities and pipeline developments.
FAQ
What is the current stock price of Viatris Ord Shs (VTRS)?
What is the market cap of Viatris Ord Shs (VTRS)?
